# Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma

> **NCT05107427** · PHASE2 · WITHDRAWN · sponsor: **4D pharma plc**

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** MRx0518
- **BIOLOGICAL:** Avelumab 20 mg/mL Intravenous Solution (IV)

## Key facts

- **NCT ID:** NCT05107427
- **Lead sponsor:** 4D pharma plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-03-01
- **Primary completion:** 2023-04
- **Final completion:** 2023-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor unable to proceed
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05107427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05107427, "Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05107427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*